HeyJaredBrian Murphy
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 25, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Jul 9, 2026
Latest articles
Severe DLBCL May Initially Manifest as Refractory Cold Agglutinin Disease - Oncology Nurse Advisor (opens the original)
Read excerpt
While cold agglutinin disease (CAD) is traditionally framed as an indolent clonal B-cell process, it can sometimes signal a severe, underlying malignancy, such as diffuse large B-cell lymphoma (DLBCL), as highlighted by a case report presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. The 73-year-old woman in the case report presented with 3 to 4 weeks of dyspnea and lower extremity edema along with laboratory findings of severe anemia (hemoglobin, 4.2 g/dL). Direct anti
Concurrent Improvement of MDS and Metastatic Melanoma With Nivolumab - Oncology Nurse Advisor (opens the original)
Read excerpt
Treatment with nivolumab for metastatic melanoma may have improved a concurrent case of therapy-related myelodysplastic syndrome (MDS) in a case report published in Current Oncology. The 67-year-old man in the case developed therapy-related MDS and profound pancytopenia following treatment for oligosecretory multiple myeloma that included chemotherapy, radiotherapy, and ultimately autologous stem cell transplantation. His therapy-related MDS required frequent platelet and packed red blood cell t
CD8+ T-Cell Count Predicts Prognosis in DLBCL Utilizing R-CHOP - Oncology Nurse Advisor (opens the original)
Read excerpt
Among patients with diffuse large B-cell lymphoma (DLBCL), a baseline peripheral CD8+ T-cell count (CD8c) may predict prognosis when receiving treatment with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP), according to a study published in the Annals of Hematology. The study found that a lower CD8c at diagnosis was a strong, independent predictor of survival. These results are surprising as CD8+ T cells are normally involved in fighting cance
ALL Pediatric Survival Rates Lower in Emerging Than Developed Countries - Oncology Nurse Advisor (opens the original)
Read excerpt
Although survival rates of patients with pediatric acute lymphoblastic leukemia (ALL) are high in developed countries, the survival rate in emerging nations, such as Mexico, is much lower, according to a 10-year study published in JNCI Cancer Spectrum. The retrospective study of 253 pediatric patients with ALL from a public hospital in Mexico City found that the 10-year overall survival (OS) rate was 58.1%. In addition, the event-free survival (EFS) of the Mexico City cohort was only 56.9%. This
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.